Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XFOR

XFOR - X4 Pharmaceuticals Inc Stock Price, Fair Value and News

$3.62-0.08 (-2.16%)
Market Closed

81/100

XFOR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

81/100

XFOR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.55

Target 3M

$4.47

Target 6M

$5

XFOR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XFOR Price Action

Last 7 days

-3.5%

Last 30 days

-15.8%

Last 90 days

-9.3%

Trailing 12 Months

-75.0%

XFOR RSI Chart

XFOR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XFOR Valuation

Market Cap

316.5M

Price/Earnings (Trailing)

-3.33

Price/Sales (Trailing)

9.32

EV/EBITDA

-2.64

Price/Free Cashflow

-3.07

XFOR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.55

Target 3M

$4.47

Target 6M

$5

XFOR Fundamentals

XFOR Revenue

Revenue (TTM)

34.0M

XFOR Earnings

Earnings (TTM)

-95.1M

Earnings Growth (Yr)

18.75%

Earnings Growth (Qtr)

-15.83%

XFOR Profitability

Operating Margin

83.24%

EBT Margin

-278.98%

Return on Equity

-154.33%

Return on Assets

-58.14%

Free Cashflow Yield

-32.57%

XFOR Investor Care

Shares Dilution (1Y)

1438.06%

Diluted EPS (TTM)

-10.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202531.4M32.8M34.0M0
20240563.0K1.1M2.6M
20205.7M5.2M3.2M3.0M
20183.6M3.3M3.7M3.2M
20172.8M3.1M3.5M3.9M
20160002.4M
20150002.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About X4 Pharmaceuticals Inc

XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEx4pharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES40

X4 Pharmaceuticals Inc Frequently Asked Questions

XFOR is the stock ticker symbol of X4 Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of X4 Pharmaceuticals Inc is 316.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XFOR's fair value in chart for subscribers.

The fair value guage provides a quick view whether XFOR is over valued or under valued. Whether X4 Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact X4 Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XFOR.

As of Wed Jan 28 2026, XFOR's PE ratio (Price to Earnings) is -3.33 and Price to Sales (PS) ratio is 9.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XFOR PE ratio will change depending on the future growth rate expectations of investors.